The F309S mutation increases factor VIII secretion in human cell line

AUTOR(ES)

Fantacini, Daianne Maciely Carvalho, Fontes, Aparecida Maria, Abreu Neto, Mário Soares de, Covas, Dimas Tadeu, Picanço-Castro, Virgínia

FONTE

Rev. Bras. Hematol. Hemoter.

DATA DE PUBLICAÇÃO

2016-06

RESUMO

ABSTRACT OBJECTIVES: The capacity of a human cell line to secrete recombinant factor VIII with a F309S point mutation was investigated, as was the effect of the addition of chemical chaperones (betaine and sodium-4-phenylbutyrate) on the secretion of factor VIII. METHODS: This work used a vector with a F309S mutation in the A1 domain to investigate FVIII production in the HEK 293 human cell line. Factor VIII activity was measured by chromogenic assay. Furthermore, the effects of chemical drugs on the culture were evaluated. RESULTS: The addition of the F309S mutation to a previously described FVIII variant increased FVIII secretion by 4.5 fold. Moreover, the addition of betaine or sodium-4-phenylbutyrate increased the secretion rate of FVIIIΔB proteins in HEK 293 cells, but the same effect was not seen for FVIIIΔB-F309S indicating that all the recombinant protein produced had been efficiently secreted. CONCLUSION: Bioengineering factor VIII expressed in human cells may lead to an efficient production of recombinant factor VIII and contribute toward low-cost coagulation factor replacement therapy for hemophilia A. FVIII-F309S produced in human cells can be effective in vivo.

Documentos Relacionados

• Bioengineering coagulation factors for improved hemophilia treatments : Comment on: the mutation F309S increases FVIII secretion in human cell line
• Permanent cell line expressing human factor VIII-related antigen established by hybridization.
• Tissue factor expression by a human kidney proximal tubular cell line in vitro: a model relevant to urinary tissue factor secretion in disease?
• Induction of plasma protein secretion in a newly established human hepatoma cell line.
• Interaction of factor VIII antigen in hemophilic plasmas with human antibodies to factor VIII.